Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XIENCE 90: 3-month DAPT in HBR Patients
NCT03218787Completed
- Sponsor
- Abbott Laboratories
- Start
- Jul 2017
- Primary completion
- Sep 2020
- Countries
- 1
01
Overview
Open-label, single-arm trial in coronary artery disease (CAD), sponsored by Abbott Laboratories. Primary endpoint: Composite Rate of All Death or All Myocardial Infarction. Started Jul 2017; status: completed.
02
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03218787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03218787.